Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer

Head Neck. 2010 Aug;32(8):1019-27. doi: 10.1002/hed.21277.

Abstract

Background: The expression of matrix metalloproteinases (MMPs) in epithelial-myoepithelial salivary gland carcinoma has not been studied previously.

Methods: Immunohistochemistry for MMP-1, -7, -9, -13, Ki-67, and HER-2, as well as HER-2 gene amplification by silver enhanced in situ hybridization was performed in a series of 12 paraffin-embedded histopathologic samples of patients from Canada and Finland.

Results: A positive MMP-13 (p = .0022), higher MMP-13 (p = .0274), and higher MMP-9 (p = .0274) index (multiplication of staining intensity by percentage of the positive cells) predicted better overall survival. In disease-specific analysis, higher MMP-9 index (p = .0327) predicted better survival. A higher volume corrected index (VCI) of Ki-67 (p = .0339) predicted worse disease-specific survival. In 1 patient, HER-2 oncogene amplification was observed.

Conclusion: MMPs and Ki-67 may have prognostic impact in epithelial-myoepithelial carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma / metabolism*
  • Carcinoma / mortality
  • Carcinoma / pathology
  • Cohort Studies
  • Female
  • Humans
  • Ki-67 Antigen / metabolism*
  • Male
  • Matrix Metalloproteinases, Secreted / metabolism*
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Receptor, ErbB-2 / metabolism*
  • Retrospective Studies
  • Salivary Gland Neoplasms / metabolism*
  • Salivary Gland Neoplasms / mortality
  • Salivary Gland Neoplasms / pathology*

Substances

  • Ki-67 Antigen
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Matrix Metalloproteinases, Secreted